Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Morphea

Does Morphea Turn Into Systemic Sclerosis?

At a Glance

No, morphea (localized scleroderma) does not turn into systemic sclerosis. They are distinct conditions. Morphea affects the skin and underlying tissues, while systemic sclerosis attacks internal organs. If systemic symptoms appear, it indicates an initial misdiagnosis, not a transformation.

No. If you have been diagnosed with localized scleroderma (also called morphea), it will not spontaneously turn into the systemic form of scleroderma that attacks internal organs [1][2]. While the names are confusingly similar and both involve skin thickening, they are widely recognized by doctors as two distinct clinical conditions [3][4].

Two Distinct Conditions

Both morphea and systemic sclerosis share similar underlying disease pathways that cause an overproduction of collagen, leading to patches of hardened or thickened skin [5][3]. However, this is largely where the similarities end.

Localized scleroderma is limited to the skin and sometimes the underlying tissues [6]. It does not attack internal organs like the heart, lungs, or kidneys, and it is not considered a life-threatening disease [7][3][4]. By contrast, systemic sclerosis is a multi-system condition that is characterized by internal organ damage, such as lung scarring (interstitial lung disease) [4].

Morphea does not transform into systemic sclerosis. In the exceptionally rare cases where patients seem to develop systemic features, it is generally because they were misdiagnosed early on or have a rare “overlap” syndrome, not because the morphea itself transformed [2][8].

How Morphea Can Spread

While morphea does not migrate to your internal organs, it can still spread or cause damage in the localized areas where it is active. Depending on the specific subtype of morphea you have (such as generalized or linear), the condition can extend beneath the surface of the skin [9]:

  • Deep Tissues: Morphea can involve the fascia (the connective tissue surrounding muscles) and the muscles beneath the skin, sometimes leading to muscle atrophy (wasting away) [10][11].
  • Bones and Joints: In severe cases, particularly linear scleroderma, it can impact bone growth, cause joint arthritis, and limit your mobility [12][13][14].
  • Facial Changes: A specific subtype of linear scleroderma (sometimes called en coup de sabre) can affect the face or scalp, leading to tissue loss or structural changes [12][15].
  • Widespread Skin Patches: Generalized morphea can cause multiple hardened skin plaques to appear across different areas of the body [9][16].

Because of these potential structural impacts, localized scleroderma still requires careful monitoring. Fortunately, there are effective medical treatments available (like topical medications, phototherapy, or systemic immunosuppressants) that can help halt the disease’s activity and prevent permanent changes to your body [9]. You do not need to carry the fear of it attacking your vital organs [7].

When to Talk to Your Doctor

Because the early skin patches of systemic sclerosis can occasionally look exactly like morphea, your doctor should evaluate you thoroughly when you are first diagnosed to ensure the correct classification [1][17]. A standard “thorough evaluation” usually relies on a careful physical exam and medical history, and it may also include specific autoantibody blood tests (like an ANA or scleroderma-specific panel) to help rule out systemic disease [1][18].

If you develop certain systemic symptoms later on, it doesn’t mean your morphea “turned into” systemic sclerosis. Instead, it might mean your care team needs to re-evaluate your initial diagnosis [2][8].

You should notify your doctor if you experience:

  • Raynaud’s phenomenon: Your fingers or toes turning stark white, blue, or red in response to cold temperatures or emotional stress [6][19].
  • Sclerodactyly: Tightening and thickening of the skin specifically on your fingers or toes, which is very rare in isolated morphea [6][19].
  • Internal symptoms: Unexplained shortness of breath, severe new-onset heartburn, or difficulty swallowing, which could suggest the type of lung or gastrointestinal involvement seen in systemic sclerosis [3][4].

Common questions in this guide

Does localized scleroderma eventually turn into systemic sclerosis?
No. Localized scleroderma, or morphea, is a distinct condition that is limited to the skin and sometimes underlying tissues. It does not spontaneously transform into the systemic form that attacks internal organs.
Can morphea spread to my internal organs?
Morphea does not migrate to internal organs like the heart, lungs, or kidneys. However, depending on the subtype, it can spread locally beneath the skin to affect deep tissues, muscles, fascia, bones, and joints.
Why might someone with morphea develop systemic sclerosis symptoms?
If a patient diagnosed with morphea develops systemic features later on, it is generally because they were initially misdiagnosed or have a rare overlap syndrome, not because the morphea itself transformed.
What symptoms indicate I might have systemic sclerosis rather than morphea?
Warning signs include Raynaud's phenomenon (fingers turning white, blue, or red in the cold), tightening skin on the fingers (sclerodactyly), unexplained shortness of breath, and severe new-onset heartburn.
How do doctors confirm my diagnosis is only morphea?
Because early systemic sclerosis can look like morphea, doctors rely on a careful physical exam and medical history. They may also order autoantibody blood tests, such as an ANA or scleroderma-specific panel, to definitively rule out systemic disease.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my physical exam, what specific subtype of localized scleroderma (morphea) do I have?
  2. 2.Did my initial diagnostic workup include any autoantibody blood tests to definitively rule out systemic sclerosis?
  3. 3.How deep does my morphea appear to go—is there any clinical evidence that it is affecting my fascia, muscle, or joints?
  4. 4.What is our plan for monitoring the activity of my morphea over the next year?
  5. 5.What medical treatments can we use right now to help halt the spread of my localized skin plaques?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Diagnosis and management of linear scleroderma in children.

    Peña-Romero AG, García-Romero MT

    Current opinion in pediatrics 2019; (31(4)):482-490 doi:10.1097/MOP.0000000000000785.

    PMID: 31157654
  2. 2

    [Morphea or localized scleroderma and extragenital lichen sclerosus].

    Moinzadeh P, Kreuter A, Krieg T, Hunzelmann N

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2018; (69(11)):892-900 doi:10.1007/s00105-018-4266-7.

    PMID: 30255259
  3. 3

    Recent Advances in Treatment of Systemic Sclerosis and Morphea.

    Teske N, Fett N

    American journal of clinical dermatology 2024; (25(2)):213-226 doi:10.1007/s40257-023-00831-2.

    PMID: 38087156
  4. 4

    [Sclerosing skin diseases].

    Sticherling M

    Der Internist 2019; (60(8)):783-791 doi:10.1007/s00108-019-0643-2.

    PMID: 31292667
  5. 5

    Sclerosing diseases of the skin.

    Kalantari Y, Meier K, Ghoreschi K, et al.

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2025; (23(10)):1282-1300 doi:10.1111/ddg.15835.

    PMID: 41030177
  6. 6

    Are systemic sclerosis and localized scleroderma (morphea) part of a common disease spectrum? A systematic review on their coexistence.

    De Rosa C, Di Marco G, Bottino V, et al.

    Clinics in dermatology 2025; (43(6)):850-858 doi:10.1016/j.clindermatol.2025.09.032.

    PMID: 41043651
  7. 7

    Incidence, prevalence, and mortality of localized scleroderma in Quebec, Canada: a population-based study.

    Ghazal S, Muntyanu A, Aw K, et al.

    Lancet regional health. Americas 2025; (44()):101044 doi:10.1016/j.lana.2025.101044.

    PMID: 40206390
  8. 8

    European Dermatology Forum S1-guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes.

    Knobler R, Moinzadeh P, Hunzelmann N, et al.

    Journal of the European Academy of Dermatology and Venereology : JEADV 2017; (31(9)):1401-1424 doi:10.1111/jdv.14458.

    PMID: 28792092
  9. 9

    Nationwide epidemiological and clinical survey of juvenile-onset morphea in Japan.

    Hamaguchi Y, Ueda-Hayakawa I, Kaneko U, et al.

    The Journal of dermatology 2025; (52(5)):860-871 doi:10.1111/1346-8138.17684.

    PMID: 40040588
  10. 10

    Localized scleroderma: anatomic MRI findings of morphea with inter-reader analysis.

    Iancau A, Attia S, Duarte Silva F, et al.

    Skeletal radiology 2025; (54(10)):2055-2065 doi:10.1007/s00256-025-04909-2.

    PMID: 40131433
  11. 11

    A Case of Extensive Debilitating Generalized Morphea.

    Sapra A, Dix R, Bhandari P, et al.

    Cureus 2020; (12(5)):e8117 doi:10.7759/cureus.8117.

    PMID: 32542170
  12. 12

    [The useful forehead, the impaired forehead, but the forehead… repaired!]

    Guerreschi P, Lacroix G, Martinot-Duquennoy V

    Annales de chirurgie plastique et esthetique 2024; (69(6)):603-610 doi:10.1016/j.anplas.2024.06.025.

    PMID: 39060145
  13. 13

    Prediction of disease relapse in a cohort of paediatric patients with localized scleroderma.

    Kurzinski KL, Zigler CK, Torok KS

    The British journal of dermatology 2019; (180(5)):1183-1189 doi:10.1111/bjd.17312.

    PMID: 30315656
  14. 14

    Inflammatory arthritis in pediatric patients with morphea.

    Kashem SW, Correll CK, Vehe RK, et al.

    Journal of the American Academy of Dermatology 2018; (79(1)):47-51.e2 doi:10.1016/j.jaad.2018.03.005.

    PMID: 29535035
  15. 15

    Parry-Romberg syndrome associated with en coup de sabre in a patient from South Sudan - a rare entity from East Africa: a case report.

    Abdelnour JGW, Abdelnour YGW, Kerollos RAB, Mahmoud ZIT

    Journal of medical case reports 2019; (13(1)):138 doi:10.1186/s13256-019-2063-2.

    PMID: 31046814
  16. 16

    Exploring the impact of paediatric localized scleroderma on health-related quality of life: focus groups with youth and caregivers.

    Zigler CK, Ardalan K, Hernandez A, et al.

    The British journal of dermatology 2020; (183(4)):692-701 doi:10.1111/bjd.18879.

    PMID: 31955419
  17. 17

    Nodular Scleroderma Revisited: Systemic Sclerosis Presenting as Annular Keloidal Sclerotic Plaques.

    Lortscher DN, Cohen PR, Bangert CA, Paravar T

    The Journal of clinical and aesthetic dermatology 2016; (9(6)):56-7.

    PMID: 27386053
  18. 18

    Anti-Centromere Antibody Positivity in a Patient with Generalized Morphea.

    Miyagawa F, Nakajima A, Akai Y, Asada H

    Case reports in dermatology 2018; (10(3)):226-230 doi:10.1159/000493180.

    PMID: 30519168
  19. 19

    Revealing Microvascular Involvement in Pediatric Localized Scleroderma Through Nailfold Capillaroscopy.

    Taşkın SN, Doğantan Ş, Esen E, et al.

    Children (Basel, Switzerland) 2025; (12(9)) doi:10.3390/children12091245.

    PMID: 41007110

This page provides educational information about the differences between morphea and systemic sclerosis. Always consult your doctor for an accurate diagnosis and a treatment plan tailored to your specific symptoms.

Get notified when new evidence is published on Scleroderma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.